Please check the following:
- {{x.value}}
FREE membership
FREE membership
Join Intelligent Investor today
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
Please enter the 5 digit verification code sent to "{{user.DayPhone}}" Change number
We cannot send you a verification code via SMS to "{{user.DayPhone}}" Change number
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
Please enter your mobile number and press send to receive a text message with a verification code.
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
Thank you
We have sent you an email with the details of your registration.
Purchase order
Sign up
Log in
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Log in
Upgrade Today
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
{{eventFunction.Name}}
{{eventFunction.EventTypeName}}
{{eventFunction.StartDate}}
{{eventFunction.EventTimings}}
{{eventFunction.VenueName}}
{{ t.Cost === 0 ? "FREE" : "$" + t.Cost.toFixed(2) }}
Quantity *
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
Congratulations!
You now have free access to InvestSMART, we look forward to helping you on your financial journey.
You now have access to Free Eureka Report Insights, We look forward to helping you on your financial journey.
You now have access to Intelligent Investor Free Insights. We look forward to helping you build a market beating stock portfolio.
Looking for more…
Intelligent Investor Membership
15-day Free Trial
- Indepth analysis of ASX listed shares
- BUY, Hold and Sell Recommendations
- Ideas Lab
- Special Reports
No thanks
Looking for more…
Eureka Report Membership
15-day Free Trial
- Alan Kohler’s Weekend Briefing
- Interviews with CEO’s & top influencers
- Money Cafe and Talking Finance
- Super Advice and Q&A with Ask Alan
No thanks
Celldex Therapeutics (NASDAQ: CLDX) - Share Price and Research
Current share price for CLDX : $39.920 1.14 (2.78%)
Currency: USD ($)
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
CLDX General Information +
| NASDAQ Code | CLDX |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 2,631 |
| CLDX Share Price | $39.920 |
| Day High | $41.660 |
| Day Low | $39.520 |
| Last Close | $41.060 |
| CLDX Share Price Movement | $1.14 ( 2.78% ) |
Prices as at 5:09, 11 May 2024
+Security prices are at best end-of-day and are indicative only.
Related Research
CLDX Financial Summary
| Operating Revenue Per Share | Price to Operating revenue | Price to free cash flow | Earnings Yield | PE Ratio | Dividend Yield | Forward Dividend Yield | Forward Earnings Yield |
|---|---|---|---|---|---|---|---|
| $0.07 | $602.78 | ($16.95) | n/a | n/a | n/a | -5.89 |
CLDX Calendar of Events
| Created Date | Changed Date | Event |
|---|---|---|
| 26 April 2024 | 26 April 2024 | Company Meeting |
FAQs about
What is the current share price of Celldex Therapeutics (CLDX)?
Celldex Therapeutics's (CLDX) current share price is $39.92. This constitutes a price movement of 6.20% when compared to the share price 7 days ago and is -23.01% below CLDX's 12-month high of $51.85 per share. Prices are delayed by at least 20 minutes.
What is the share price movement for Celldex Therapeutics (CLDX)?
Relative to the previous close share price of $41.06, Celldex Therapeutics's (CLDX) current share price of $39.92 constitutes a movement of ($1.14) or -2.78%. Celldex Therapeutics's (CLDX) share price movement is -6.20% when compared to 7 days ago and is -23.01% below CLDX's 52-week high of $51.85.
What is the 52-week high share price for Celldex Therapeutics (CLDX)?
Celldex Therapeutics's (CLDX) 52-week high is $51.85 which was reached on 2 Mar 2024. Relative to this, CLDX's current share price of $39.92 constitutes a ($11.93) or -23.01% drop since that high of $51.85 per CLDX share.
What is the 52-week low share price for Celldex Therapeutics (CLDX)?
Celldex Therapeutics's (CLDX) 52-week low is $22.61 which was reached on 28 Oct 2023. Relative to this, CLDX's current share price of $39.92 constitutes a $17.31 or 76.56% gain since that low of $22.61 per CLDX share.
What is the daily average trading volume for Celldex Therapeutics (CLDX)?
Over the last 12 months, Celldex Therapeutics (CLDX) has a daily average trading volume of 182,616 CLDX shares per day.
When does Celldex Therapeutics (CLDX) release its next Annual Report?
Celldex Therapeutics (CLDX) will release its next Annual Report on n/a. Celldex Therapeutics's (CLDX) last annual report was released on n/a.
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
